Evidence map›Paper›PMID 31325144›Full record

Trial reportJournal of neuro-oncology2019

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Sied Kebir, Christina Schaub, Nina Junold, Elke Hattingen, Niklas Schäfer, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Roland Goldbrunner, Norbert Galldiks and 19 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sied KebirDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany. Sied.Kebir@uk-essen.de.ORCID http://orcid.org/0000-0002-0678-5852
Christina SchaubDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Nina JunoldDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Elke HattingenInstitute of Neuroradiology, University of Frankfurt, Frankfurt, Germany.
Niklas SchäferDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Joachim P SteinbachDr. Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany.
Astrid WeyerbrockDepartment of Neurosurgery, University of Freiburg, Freiburg, Germany.
Peter HauDepartment of Neurology and Wilhelm Sander Neurooncology Unit, University of Regensburg, Regensburg, Germany.
Roland GoldbrunnerCenter for Neurosurgery, University of Cologne, Cologne, Germany.
Norbert GalldiksDepartment of Neurology, University of Cologne, Cologne, Germany.
Johannes WellerDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Frederic MackDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Theophilos TzaridisDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Oliver BährDr. Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany.
Clemens SeidelDepartment of Radiation Oncology, University of Leipzig, Leipzig, Germany.
Uwe SchlegelDepartment of Neurology, Knappschaftskrankenhaus Klinikum Der Ruhr-Universität Bochum, Bochum, Germany.
Friederike Schmidt-GrafDepartment of Neurology, Klinikum Rechts Der Isar, Technical University of Munich (TUM), Munich, Germany.
Veit RohdeDepartment of Neurosurgery, Georg-August-University, Göttingen, Germany.
Christian BorchersDepartment of Neurology, Nordwest-Krankenhaus Sanderbusch, Sande, Germany.
Ghazaleh TabatabaiInterdisciplinary Division of Neuro-Oncology, Departments of Neurology & Neurosurgery, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University Tübignen, Tübingen, Germany.
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
Michael SabelDepartment of Neurosurgery, Medizinische Fakultät, Heinrich-Heine-Universität, Düsseldorf, Germany.
Rüdiger GerlachDepartment of Neurosurgery, HELIOS Klinikum Erfurt, Erfurt, Germany.
Dietmar KrexDepartment of Neurosurgery, Technical University Dresden, Dresden, Germany.
Claus BelkaDepartment of Radiation Oncology, LMU Munich, Munich, Germany.
Hartmut VatterDepartment of Neurosurgery, University of Bonn Medical Center, Bonn, Germany.
Martin ProescholdtDepartment of Neurosurgery, University of Regensburg, Regensburg, Germany.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Ulrich HerrlingerDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.

Funding

Roche not applicable
6 · The paper itself

Abstract

purposeThe phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment onset.

methodsMRIs at baseline (before treatment onset) were analyzed for T1-hyperintense and diffusion-restricted lesions; as well as the presence of both hyperintense and diffusion-restricted (double positive) lesions. The MRI findings were correlated with overall and progression-free survival.

resultsMRI scans were evaluable in 71% of the GLARIUS modified intention-to-treat population (n = 121 of 170; 88 patients in the BEV/IRI arm, and 33 patients in the TMZ control arm). Diffusion-restricted and T1 hyperintense lesions were present in 60% and 65% of patients in BEV/IRI arm, while 57% and 63% were found in the TMZ arm, respectively. Double positive lesions were found in 37% of BEV/IRI patients and in 39% of TMZ patients. Neither the presence of T1-hyperintense, diffusion-restricted lesions, nor double positive lesions were associated with improved survival.

conclusionsBaseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain NeoplasmsCamptothecinDacarbazineFemaleFollow-Up StudiesGlioblastomaHumansIrinotecanMagnetic Resonance ImagingMaleMiddle AgedPrognosisBevacizumabCamptothecinDacarbazineIrinotecanTemozolomideBevacizumabIrinotecanMRINewly diagnosed MGMT-non-methylated glioblastomaPredictive and prognostic implications

Identifiers

PMID31325144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.